Details of Disease

General Information of Disease (ID: DISZDG3U)

• Disease Name: Sarcoma
• Synonyms: tumour of soft tissue and skeleton; tumor of soft tissue and skeleton; sarcoma; sarcoma of soft tissue and bone; mesenchymal tumor, malignant; sarcoma, malignant; sarcoma of the soft tissue and bone
• Disease Class: 2A60-2C35: Sarcoma
• Definition: A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.
• Disease Hierarchy:
  DISAT1Z9: Advanced cancer
  DISZDG3U: Sarcoma
• ICD Code: ICD-11: ICD-11: 2A60-2C35
• Disease Identifiers:
  MONDO ID: MONDO_0005089
  MESH ID: D012509
  UMLS CUI: C1261473
  MedGen ID: 224714
  HPO ID: HP:0100242
  SNOMED CT ID: 1187396000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 14 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Angiotensin-(1-7)	DM76GZ0	Phase 3	Small molecular drug	[1]
NKTR 214	DM376WT	Phase 3	NA	[2]
O6-Benzylguanine alkylade	DM3L2GT	Phase 3	NA	[3]
Ombrabulin	DM25HY3	Phase 3	Small molecular drug	[4]
Ridaforolimus	DMLHEU7	Phase 3	Small molecular drug	[5]
Rivoceranib	DM13V0P	Phase 3	Small molecular drug	[6]
Cancer vaccine	DM03BGT	Phase 2	NA	[7]
MORAb-004	DMGK1JE	Phase 2	NA	[8]
PT-107	DMX1H4I	Phase 2	NA	[9]
AU101	DMLAKPI	Phase 1/2	NA	[10]
CTCE-9908	DM95XR8	Phase 1/2	NA	[11]
NY-ESO-1/LAGE-1-specific T-cells	DM1AT65	Phase 1/2	NA	[12]
Anti-GD2-CAR engineered T cells	DMCNFZG	Phase 1	CAR T Cell Therapy	[13]
Tetrandrine	DMAOJBX	Phase 1	Small molecular drug	[2]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Robatumumab	DMOEQO1	Discontinued in Phase 2	Monoclonal antibody	[14]
RX-465	DMCCTVI	Terminated	NA	[15]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 125 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AMHR2	TTZDCPK	Limited	Altered Expression	[16]
ATM	TTKBM7V	Limited	Biomarker	[17]
CD248	TTYJWT7	Limited	Altered Expression	[18]
CHEK2	TT9ABMF	Limited	Biomarker	[19]
DEPDC1	TT8S9CM	Limited	Biomarker	[20]
DICER1	TTTEOPU	Limited	Biomarker	[21]
EGLN1	TT9ISBX	Limited	Altered Expression	[22]
FABP3	TT3TGLR	Limited	Biomarker	[23]
FAP	TTGPQ0F	Limited	Biomarker	[24]
FLT3	TTGJCWZ	Limited	Biomarker	[25]
MST1R	TTBQ3OC	Limited	Biomarker	[26]
NR4A3	TTJQB49	Limited	Biomarker	[27]
PLOD2	TT8MEUD	Limited	Biomarker	[28]
RICTOR	TT143WL	Limited	Altered Expression	[29]
TYRO3	TTIEMFN	Limited	Altered Expression	[30]
XPO1	TTCJUR4	Limited	Altered Expression	[31]
CSF2RA	TT6MP2Z	Disputed	Altered Expression	[32]
CSF2RB	TTPYS82	Disputed	Biomarker	[32]
IL3RA	TTENHJ0	Disputed	Altered Expression	[32]
ANTXR2	TTOD34I	moderate	Altered Expression	[33]
ATM	TTKBM7V	Moderate	Autosomal dominant	[34]
ATR	TT8ZYBQ	Moderate	Autosomal dominant	[34]
AZGP1	TTUPYLV	moderate	Altered Expression	[35]
BRCA2	TTUARD6	Moderate	Autosomal dominant	[36]
CLDN4	TTMTS9H	moderate	Altered Expression	[37]
ENPP2	TTSCIM2	moderate	Altered Expression	[38]
ESRRB	TTKF0XS	moderate	Biomarker	[39]
FOXO1	TTLRVIA	moderate	Genetic Variation	[40]
GLI1	TTJOMH6	moderate	Biomarker	[41]
ITGAM	TTB69FJ	moderate	Biomarker	[42]
NACC1	TT4AQ5F	moderate	Altered Expression	[43]
NTRK3	TTXABCW	moderate	Biomarker	[44]
RGS6	TTJ96M8	moderate	Genetic Variation	[45]
ROR1	TTDEJAU	moderate	Biomarker	[46]
STK4	TTCPLVN	moderate	Genetic Variation	[47]
TUSC2	TTJ8O14	moderate	Biomarker	[48]
ABHD6	TTSINOV	Strong	Biomarker	[49]
ABL2	TT1A6HL	Strong	Biomarker	[50]
AMOT	TTI48OS	Strong	Posttranslational Modification	[51]
ANO1	TTOJI4S	Strong	Altered Expression	[52]
ATRAID	TTFLIKM	Strong	Genetic Variation	[53]
BPI	TTXCSDR	Strong	Biomarker	[54]
CA9	TT2LVK8	Strong	Biomarker	[55]
CD274	TT8ZLTI	Strong	Biomarker	[56]
CD3E	TTZAT79	Strong	Altered Expression	[57]
CD6	TTMF6KC	Strong	Genetic Variation	[58]
CDK4	TT0PG8F	Strong	Genetic Variation	[59]
CDKN2C	TTBRUGA	Strong	Genetic Variation	[53]
CLIC1	TT8KZG6	Strong	Biomarker	[60]
CPE	TTXPWO6	Strong	Altered Expression	[61]
CRTC1	TT4GO0F	Strong	Genetic Variation	[62]
CSF1R	TT7MRDV	Strong	Biomarker	[63]
CSF2	TTNYZG2	Strong	Biomarker	[64]
CSK	TTX6F0Q	Strong	Altered Expression	[65]
CSPG4	TT7MYXI	Strong	Biomarker	[66]
CTAG1A	TTE5ITK	Strong	Biomarker	[67]
DHCR24	TTTK0NH	Strong	Biomarker	[68]
ELAVL1	TTPC9D0	Strong	Altered Expression	[69]
EML4	TT92GY4	Strong	Biomarker	[70]
EZR	TTE47YC	Strong	Biomarker	[71]
FER	TTRA9G0	Strong	Biomarker	[25]
FES	TTLBY21	Strong	Biomarker	[72]
FGFR4	TT1KX2S	Strong	Genetic Variation	[73]
FLT4	TTDCBX5	Strong	Altered Expression	[74]
FPR1	TT5Y4EM	Strong	Biomarker	[75]
FSHR	TTZFDBT	Strong	Biomarker	[76]
G3BP1	TTG0R8Z	Strong	Altered Expression	[77]
GABRG2	TT06RH5	Strong	Biomarker	[78]
GHRHR	TTG4R8V	Strong	Biomarker	[79]
GP6	TTTJUVZ	Strong	Biomarker	[80]
GRHL2	TTUGH4C	Strong	Altered Expression	[81]
HBEGF	TT15SL0	Strong	Biomarker	[82]
HDGF	TTKGV26	Strong	Altered Expression	[83]
HRAS	TT28ZON	Strong	Biomarker	[84]
ID2	TTW8A5N	Strong	Altered Expression	[85]
JUN	TTS7IR5	Strong	Altered Expression	[86]
KAT6A	TT6O1J0	Strong	Biomarker	[87]
KCNJ4	TTXF0ZW	Strong	Biomarker	[88]
KIT	TTX41N9	Strong	Altered Expression	[89]
LAG3	TTNVXAW	Strong	Altered Expression	[90]
LATS2	TTML7FG	Strong	Genetic Variation	[91]
LCK	TT860QF	Strong	Biomarker	[92]
LSS	TT7O8ZA	Strong	Biomarker	[93]
LYVE1	TTG8DNU	Strong	Biomarker	[94]
MAGEA3	TTWSKHD	Strong	Altered Expression	[95]
MAGEC2	TTKGUEB	Strong	Biomarker	[96]
MCL1	TTL53M6	Strong	Altered Expression	[97]
MDM4	TT9OUDQ	Strong	Altered Expression	[98]
MELK	TTBZOTY	Strong	Biomarker	[99]
MLANA	TT362RB	Strong	Altered Expression	[100]
MLH1	TTISG27	Strong	Biomarker	[101]
MSH2	TTCAWRT	Strong	Altered Expression	[102]
MTAP	TTDBX7N	Strong	Genetic Variation	[103]
NAPRT	TTVR1FW	Strong	Biomarker	[104]
NME1	TTDY8JH	Strong	Altered Expression	[105]
NPY1R	TTRK9JT	Strong	Altered Expression	[106]
PDCD1	TTNBFWK	Strong	Biomarker	[107]
PDGFB	TTQA6SX	Strong	Biomarker	[108]
PDGFRA	TT8FYO9	Strong	Biomarker	[109]
PLD2	TTRLMKF	Strong	Altered Expression	[110]
PLK2	TT976FS	Strong	Biomarker	[96]
PRAME	TTPH7T0	Strong	Biomarker	[111]
RBPJ	TT72D4Z	Strong	Biomarker	[112]
SIK1	TT1H6LC	Strong	Genetic Variation	[113]
SLC9A3	TTFZVPO	Strong	Biomarker	[114]
SMARCA4	TTVQEZS	Strong	Genetic Variation	[115]
SOX2	TTCNOT6	Strong	Altered Expression	[116]
SRC	TT6PKBN	Strong	Biomarker	[117]
SSTR2	TTZ6T9E	Strong	Altered Expression	[118]
STMN1	TT7W5OT	Strong	Biomarker	[119]
STS	TTHM0R1	Strong	Biomarker	[120]
TACC3	TTQ4UFD	Strong	Altered Expression	[121]
TLN1	TTQSMFG	Strong	Genetic Variation	[99]
TNFRSF21	TT8UA0T	Strong	Altered Expression	[122]
TP53	TT7SBF5	Strong	Autosomal dominant	[123]
ULK1	TT4D7MJ	Strong	Biomarker	[124]
VEGFC	TT0QUFV	Strong	Altered Expression	[74]
VIPR1	TTCL30I	Strong	Altered Expression	[125]
WRN	TT2H5WQ	Strong	Genetic Variation	[126]
WT1	TTZ8UT4	Strong	Altered Expression	[127]
YAP1	TT8UN2D	Strong	Biomarker	[128]
YES1	TT0SQ8J	Strong	Biomarker	[129]
ZAP70	TTUMHT8	Strong	Biomarker	[57]
ZWINT	TTWY768	Strong	Biomarker	[130]
GSTP1	TT40K12	Definitive	Biomarker	[131]

This Disease Is Related to 3 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCB5	DTKVEXO	Strong	Biomarker	[132]
SLC25A16	DTNU9EW	Strong	Biomarker	[133]
SLC27A5	DT0TQS3	Strong	Biomarker	[134]

This Disease Is Related to 228 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACSL3	OT3MWER1	Limited	Biomarker	[135]
ACSL4	OTI71MUJ	Limited	Biomarker	[135]
ATP23	OT303R2T	Limited	Biomarker	[136]
BANF1	OTP7Z38L	Limited	Altered Expression	[137]
DEPDC1B	OTMVFOT1	Limited	Altered Expression	[20]
ERCC5	OTQAKFJM	Limited	Altered Expression	[138]
GADD45A	OTDRV63V	Limited	Biomarker	[139]
GNAS	OTMH8BKJ	Limited	Genetic Variation	[140]
LATS1	OTOOCG4R	Limited	Genetic Variation	[141]
LIN28B	OTVWP0FN	Limited	Biomarker	[142]
MITF	OT6XJCZH	Limited	Biomarker	[143]
NCOA2	OTMQFPBB	Limited	Biomarker	[144]
NDC80	OTS7D306	Limited	Altered Expression	[145]
NPAS2	OTMRT2TS	Limited	Genetic Variation	[146]
NUTM2A	OTQ4VQXE	Limited	Genetic Variation	[147]
OGA	OT7ZBWT1	Limited	Genetic Variation	[148]
PLAGL1	OTZAO900	Limited	Posttranslational Modification	[149]
POLM	OT0SRIP4	Limited	Biomarker	[136]
PRUNE1	OTQ3UHWQ	Limited	Biomarker	[150]
RANBP2	OTFG5CVF	Limited	Genetic Variation	[151]
RNASE3	OTVE2XD1	Limited	Genetic Variation	[152]
RPL17	OTTYMPS6	Limited	Biomarker	[107]
SART3	OTC1AM7S	Limited	Genetic Variation	[153]
SKI	OT4KJ8F6	Limited	Biomarker	[130]
SMARCA1	OT0Y6PTU	Limited	Biomarker	[137]
SPATA2	OTOA45GL	Limited	Biomarker	[107]
SSX1	OTZ7NRCY	Limited	Genetic Variation	[154]
TGFBR3	OTQOOUC4	Limited	Biomarker	[148]
THY1	OTVONVTB	Limited	Biomarker	[124]
TOPBP1	OT6UPZPD	Limited	Altered Expression	[155]
TSPAN1	OTZQPIYK	Limited	Biomarker	[156]
AMER1	OT8EFJPM	moderate	Biomarker	[157]
APC	OTKV0TIK	Moderate	Autosomal dominant	[34]
AQP5	OT77GBY8	moderate	Biomarker	[158]
ATM	OTQVOHLT	Moderate	Autosomal dominant	[34]
ATR	OTH0OP1J	Moderate	Autosomal dominant	[34]
BRCA2	OTF1XSV1	Moderate	Autosomal dominant	[36]
CD109	OTDADBM4	moderate	Biomarker	[159]
CHAMP1	OTBGWU86	moderate	Genetic Variation	[160]
CIB2	OT9ZJX1I	moderate	Genetic Variation	[161]
CLEC11A	OT9KBH7C	moderate	Altered Expression	[162]
CORO7	OTG7MEAJ	moderate	Biomarker	[163]
ERCC2	OT1C8HQ4	Moderate	Autosomal recessive	[34]
IMPACT	OTQ923OB	moderate	Biomarker	[164]
ING2	OT6H0EWF	moderate	Biomarker	[165]
KLLN	OTV3FPH0	moderate	Genetic Variation	[166]
KRT7	OTLT3JFN	moderate	Biomarker	[167]
MAD2L1	OTXNGZCG	moderate	Altered Expression	[168]
MAPK8IP2	OTDUHLN0	moderate	Biomarker	[109]
MOV10L1	OTP978LK	moderate	Genetic Variation	[160]
MYCL	OT1MFQ5U	moderate	Genetic Variation	[169]
NF1	OTC29NHH	moderate	Biomarker	[170]
PIWIL2	OT1PXQIF	moderate	Biomarker	[171]
PRB2	OTAD4JZ0	moderate	Altered Expression	[172]
PRDM10	OTDDWU5Q	moderate	Genetic Variation	[173]
PRF1	OTFVXD7H	moderate	Genetic Variation	[174]
PRIMA1	OT9ITT3P	moderate	Biomarker	[175]
RBL2	OTBQSOE6	moderate	Biomarker	[172]
SMARCB1	OT2LP7LJ	moderate	Biomarker	[176]
STK3	OTLNSCQD	moderate	Biomarker	[47]
TPM4	OTN4YLYR	moderate	Biomarker	[177]
AADAC	OT8VACT2	Strong	Altered Expression	[178]
ABRAXAS1	OT1K4J80	Strong	Genetic Variation	[179]
ACAN	OTUOCW8K	Strong	Biomarker	[180]
ADARB1	OTGKSZEV	Strong	Altered Expression	[181]
ADGRG2	OTPAD5S1	Strong	Altered Expression	[182]
AFAP1L1	OTWNTNDB	Strong	Biomarker	[183]
AHRR	OTSJ12W6	Strong	Biomarker	[87]
AMFR	OTQRX7LC	Strong	Altered Expression	[184]
ANKRD36B	OT3MW415	Strong	Biomarker	[185]
ARAP1	OTINOJJ7	Strong	Biomarker	[75]
ARHGAP1	OT0H2ZBZ	Strong	Biomarker	[75]
ARSF	OTC0L12N	Strong	Altered Expression	[186]
ASPSCR1	OTXTOD10	Strong	Altered Expression	[187]
ATF1	OT251CI0	Strong	Altered Expression	[188]
ATRX	OT77RSQW	Strong	Biomarker	[189]
BATF3	OTI61WXQ	Strong	Biomarker	[190]
BRINP1	OTEUVSCP	Strong	Altered Expression	[191]
BTC	OTW4B2O0	Strong	Genetic Variation	[192]
C16orf96	OTE0B1QV	Strong	Biomarker	[132]
CALB2	OTSNMCG9	Strong	Altered Expression	[193]
CALD1	OTNJKJ6Q	Strong	Biomarker	[194]
CAPN6	OT8K5PR5	Strong	Altered Expression	[195]
CAVIN2	OTFHHDRU	Strong	Biomarker	[196]
CBX3	OTOP9RLD	Strong	Altered Expression	[197]
CCAR2	OTLUDG5T	Strong	Biomarker	[191]
CCN3	OTOW5YL4	Strong	Altered Expression	[198]
CCS	OTXHT3QO	Strong	Biomarker	[199]
CD247	OT45FGUX	Strong	Altered Expression	[57]
CD3D	OTRBLP0R	Strong	Altered Expression	[57]
CD82	OTH8MC64	Strong	Altered Expression	[200]
CD99	OTPUZ5DE	Strong	Altered Expression	[201]
CHSY1	OTB1XSSF	Strong	Altered Expression	[202]
CMAS	OTFQJG3C	Strong	Biomarker	[203]
CNMD	OTHND8EL	Strong	Biomarker	[204]
COL9A1	OTWBR27Y	Strong	Altered Expression	[205]
COL9A2	OT1ZBDBV	Strong	Altered Expression	[205]
COL9A3	OTCUJOEK	Strong	Altered Expression	[205]
COPB2	OT82JIGC	Strong	Biomarker	[206]
CREB3L1	OT2JHIHM	Strong	Genetic Variation	[207]
CREB3L2	OT09MHV0	Strong	Genetic Variation	[207]
CTAG1B	OTIQGW6U	Strong	Biomarker	[67]
CUL4A	OTTBV70J	Strong	Altered Expression	[208]
CYFIP2	OTCAY35T	Strong	Biomarker	[209]
DAXX	OTX6O7PL	Strong	Biomarker	[210]
DCLRE1C	OTW3KB1I	Strong	Biomarker	[211]
DCTN1	OT5B51FJ	Strong	Genetic Variation	[151]
DDIT3	OTI8YKKE	Strong	Biomarker	[212]
DDX53	OTHK3EGZ	Strong	Biomarker	[213]
DES	OTI09KBW	Strong	Biomarker	[214]
DROSHA	OTCE68KZ	Strong	Genetic Variation	[152]
DUSP12	OT8WB1YB	Strong	Biomarker	[215]
DYNLL1	OTR69LHT	Strong	Biomarker	[216]
EEF1E1	OTRA6XOB	Strong	Genetic Variation	[53]
ENDOU	OTB7OF7Y	Strong	Genetic Variation	[217]
ESD	OTUSIBPS	Strong	Altered Expression	[218]
ESPL1	OTMGEVOK	Strong	Biomarker	[219]
ETV4	OT8C98UZ	Strong	Biomarker	[220]
ETV5	OTE2OBM4	Strong	Genetic Variation	[220]
EXOSC6	OTAC10N6	Strong	Genetic Variation	[217]
EXTL3	OT2BRUBN	Strong	Altered Expression	[202]
FAU	OTGTVOWK	Strong	Altered Expression	[221]
FBP2	OT9R1LF7	Strong	Altered Expression	[222]
FBXW4	OTEGSZOX	Strong	Altered Expression	[178]
FEV	OTYEC4IR	Strong	Biomarker	[223]
FGFRL1	OT8HZ3ZL	Strong	Altered Expression	[224]
FLCN	OTVM78XM	Strong	Biomarker	[217]
FLI1	OT0EV3LX	Strong	Biomarker	[225]
FLII	OT7G9JG6	Strong	Biomarker	[225]
FOXL2	OTFRQUYL	Strong	Biomarker	[226]
FOXO4	OT90X9LN	Strong	Biomarker	[227]
FRZB	OTTO3DPY	Strong	Biomarker	[228]
FZD3	OTIWDN78	Strong	Altered Expression	[229]
GAB1	OTQKE6V4	Strong	Biomarker	[230]
GPC5	OT8NR7GC	Strong	Biomarker	[231]
GPRC5A	OTPOCWR7	Strong	Biomarker	[232]
HAUS8	OTLEFUOA	Strong	Biomarker	[233]
HIRA	OTON40EJ	Strong	Biomarker	[88]
HNRNPM	OTFU3OEZ	Strong	Altered Expression	[234]
IGFALS	OTTWCZYM	Strong	Genetic Variation	[235]
IRX2	OTBHXXQ2	Strong	Biomarker	[236]
JAZF1	OTXTYSYD	Strong	Genetic Variation	[237]
KCMF1	OTVTKFAU	Strong	Altered Expression	[238]
KCNK6	OTCY281R	Strong	Biomarker	[239]
KIF22	OTY6X6BL	Strong	Biomarker	[240]
KLF3	OTIIAC18	Strong	Altered Expression	[241]
LAMTOR1	OTIBJBW9	Strong	Genetic Variation	[53]
LARP6	OTUQ9QS9	Strong	Biomarker	[242]
LCP1	OTK61F2A	Strong	Biomarker	[243]
LRRC15	OTX7JL8H	Strong	Altered Expression	[244]
MAFK	OTZJUE4P	Strong	Genetic Variation	[53]
MAML3	OTZFV53Z	Strong	Biomarker	[245]
MCM2	OTGGORIQ	Strong	Altered Expression	[246]
MCM3	OTOOHQPM	Strong	Biomarker	[206]
MEF2A	OTV2SF6E	Strong	Biomarker	[247]
MGA	OTTLB216	Strong	Genetic Variation	[248]
MPIG6B	OTVNKQWA	Strong	Genetic Variation	[249]
MRTFB	OT9OXGS9	Strong	Biomarker	[250]
MUC6	OTPVL723	Strong	Biomarker	[251]
MYL12B	OTXMLQOT	Strong	Altered Expression	[252]
MYL2	OT78PC0C	Strong	Altered Expression	[252]
MYL9	OT6B22JB	Strong	Altered Expression	[252]
MYOD1	OTV2S79X	Strong	Genetic Variation	[253]
MYOG	OTPLJKFA	Strong	Biomarker	[250]
NANS	OTMQ2FUH	Strong	Biomarker	[254]
NAPSA	OT6F8IAL	Strong	Altered Expression	[255]
NFATC2	OTK5T6HZ	Strong	Biomarker	[256]
NKD2	OTCYT3I6	Strong	Biomarker	[236]
NKX2-2	OTDCOYNG	Strong	Altered Expression	[257]
NMB	OT4NLN6H	Strong	Altered Expression	[258]
OBP2A	OTBIJ5TI	Strong	Biomarker	[240]
ODF2L	OTJLJ65L	Strong	Biomarker	[259]
OS9	OTB5B2TY	Strong	Genetic Variation	[260]
P2RX6	OT1FNTXA	Strong	Altered Expression	[261]
PARP9	OT7K4494	Strong	Biomarker	[134]
PATZ1	OT0X9WGR	Strong	Biomarker	[262]
PAX3	OTN5PJZV	Strong	Biomarker	[263]
PAX7	OTDMQRPO	Strong	Biomarker	[264]
PHF11	OT5F6LUP	Strong	Biomarker	[259]
PIK3AP1	OTMW1B47	Strong	Biomarker	[259]
PIWIL1	OT7CRGZ3	Strong	Altered Expression	[265]
PLIN2	OTRXJ9UN	Strong	Altered Expression	[266]
PLPP2	OT0BQAXX	Strong	Altered Expression	[181]
PMS2	OTNLWTMI	Strong	Biomarker	[267]
POT1	OTNBXJCQ	Strong	Genetic Variation	[268]
POU4F1	OTMHYGWQ	Strong	Altered Expression	[125]
PPP1R11	OTSHYPPW	Strong	Biomarker	[269]
PPP1R1A	OTGTAGCV	Strong	Biomarker	[270]
PPP2R5E	OT8GPFT5	Strong	Genetic Variation	[271]
PRAP1	OT48QD82	Strong	Biomarker	[272]
PSMD4	OTH1VZTM	Strong	Altered Expression	[186]
PTPRG	OT9N2WOF	Strong	Genetic Variation	[273]
PTTG1IP	OTX21QTE	Strong	Altered Expression	[274]
RBP1	OTRP1MFC	Strong	Biomarker	[275]
REST	OTLL92LQ	Strong	Altered Expression	[276]
RITA1	OTUH8IPS	Strong	Biomarker	[277]
RND3	OTXMXPIH	Strong	Biomarker	[278]
ROM1	OTE7H0YV	Strong	Biomarker	[279]
RPS6	OTT4D1LN	Strong	Altered Expression	[280]
RRBP1	OT4ZTPTM	Strong	Genetic Variation	[151]
RREB1	OT62460U	Strong	Biomarker	[250]
RUSC2	OT0EKMVR	Strong	Biomarker	[99]
S100A1	OT1F2G4J	Strong	Biomarker	[281]
SALL2	OTQWI68Q	Strong	Biomarker	[282]
SCG2	OTXWUQQL	Strong	Biomarker	[283]
SERPINA5	OTTZXPGD	Strong	Biomarker	[284]
SERPINB9	OTJ811IF	Strong	Biomarker	[130]
SH2B1	OTJZO2CI	Strong	Biomarker	[285]
SLAMF1	OTBTT3ZQ	Strong	Biomarker	[286]
SLURP1	OT89YD2E	Strong	Biomarker	[287]
SP3	OTYDQZ1T	Strong	Altered Expression	[288]
SRSF1	OTF61HOV	Strong	Altered Expression	[186]
SSX2	OT2Z6RLL	Strong	Biomarker	[289]
STOM	OTC8R6EH	Strong	Biomarker	[290]
SYN1	OTMNPWC1	Strong	Biomarker	[291]
TAF12	OTQZII5O	Strong	Genetic Variation	[292]
TCL1B	OT4CSO39	Strong	Biomarker	[291]
TIA1	OTGPN3P8	Strong	Altered Expression	[293]
TLE1	OT50MRZ1	Strong	Altered Expression	[201]
TP53	OTIE1VH3	Strong	Autosomal dominant	[123]
TPPP2	OTI3WA6X	Strong	Genetic Variation	[53]
TPPP3	OTU8VUIG	Strong	Biomarker	[188]
TSPAN31	OT8WQ83R	Strong	Biomarker	[254]
TTF1	OT4K90WD	Strong	Biomarker	[294]
TTL	OTSS1CK4	Strong	Biomarker	[295]
MAML2	OT1TSVAR	Definitive	Biomarker	[296]
RB1	OT9VMY7B	Definitive	Biomarker	[297]
TFE3	OTM99ZWH	Definitive	Altered Expression	[298]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 582).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10;27(8):1262-7.
• [4] ClinicalTrials.gov (NCT00699517) A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies. U.S. National Institutes of Health.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7884).
• [6] ClinicalTrials.gov (NCT04072042) BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS). U.S. National Institutes of Health.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010155)
• [8] ClinicalTrials.gov (NCT01574716) Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE). U.S. National Institutes of Health.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035243)
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6.
• [12] ClinicalTrials.gov (NCT01567891) Autologous T Cells Expressing Enhanced TCRs Specific for NYESO-1/LAGE in Patients With Ovarian Cancer. U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027277)
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008498)
• [16] Mllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.Gynecol Oncol. 2008 Jan;108(1):141-8. doi: 10.1016/j.ygyno.2007.09.010. Epub 2007 Nov 7.
• [17] Radiation and ATM inhibition: the heart of the matter.J Clin Invest. 2014 Aug;124(8):3289-91. doi: 10.1172/JCI77195. Epub 2014 Jul 18.
• [18] CD248: A therapeutic target in cancer and fibrotic diseases.Oncotarget. 2019 Jan 29;10(9):993-1009. doi: 10.18632/oncotarget.26590. eCollection 2019 Jan 29.
• [19] Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.Breast Cancer Res Treat. 2011 Nov;130(1):207-15. doi: 10.1007/s10549-011-1548-5. Epub 2011 May 12.
• [20] Prognostic role of XTP1/DEPDC1B and SDP35/DEPDC1A in high grade soft-tissue sarcomas.Histol Histopathol. 2018 Jun;33(6):597-608. doi: 10.14670/HH-11-959. Epub 2018 Jan 3.
• [21] An update on the central nervous system manifestations of DICER1 syndrome.Acta Neuropathol. 2020 Apr;139(4):689-701. doi: 10.1007/s00401-019-01997-y. Epub 2019 Apr 5.
• [22] Analysis of HIF-1a and its regulator, PHD2, in retroperitoneal sarcomas: clinico-pathologic implications.Cancer Biol Ther. 2010 Feb;9(4):303-11. doi: 10.4161/cbt.9.4.10744. Epub 2009 Dec 22.
• [23] Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma.Virchows Arch. 2017 Sep;471(3):355-362. doi: 10.1007/s00428-017-2172-5. Epub 2017 Jun 22.
• [24] Integral membrane protease fibroblast activation protein sensitizes fibrosarcoma to chemotherapy and alters cell death mechanisms.Apoptosis. 2015 Nov;20(11):1483-98. doi: 10.1007/s10495-015-1166-5.
• [25] Assessment of Molecular Markers in AML Patients: A Hospital-Based Study in Lebanon.Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S80-4. doi: 10.1016/j.clml.2015.02.011.
• [26] IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.Carcinogenesis. 2011 Aug;32(8):1151-6. doi: 10.1093/carcin/bgr086. Epub 2011 May 11.
• [27] PGR Gene Fusions Identify a Molecular Subset of Uterine Epithelioid Leiomyosarcoma With Rhabdoid Features.Am J Surg Pathol. 2019 Jun;43(6):810-818. doi: 10.1097/PAS.0000000000001239.
• [28] A Feedback Loop between Hypoxia and Matrix Stress Relaxation Increases Oxygen-Axis Migration and Metastasis in Sarcoma.Cancer Res. 2019 Apr 15;79(8):1981-1995. doi: 10.1158/0008-5472.CAN-18-1984. Epub 2019 Feb 18.
• [29] From PTEN loss of expression to RICTOR role in smooth muscle differentiation: complex involvement of the mTOR pathway in leiomyosarcomas and pleomorphic sarcomas.Mod Pathol. 2012 Feb;25(2):197-211. doi: 10.1038/modpathol.2011.163. Epub 2011 Nov 11.
• [30] Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.Br J Cancer. 2017 Dec 5;117(12):1787-1797. doi: 10.1038/bjc.2017.354. Epub 2017 Oct 12.
• [31] Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IB and Downregulation of Survivin.Clin Cancer Res. 2017 Aug 1;23(15):4301-4311. doi: 10.1158/1078-0432.CCR-16-2632. Epub 2017 Mar 17.
• [32] Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.Br J Haematol. 2009 Feb;144(3):376-87. doi: 10.1111/j.1365-2141.2008.07491.x. Epub 2008 Nov 13.
• [33] CMG2 Expression Is an Independent Prognostic Factor for Soft Tissue Sarcoma Patients.Int J Mol Sci. 2017 Dec 7;18(12):2648. doi: 10.3390/ijms18122648.
• [34] Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016 Sep;17(9):1261-71. doi: 10.1016/S1470-2045(16)30147-4. Epub 2016 Aug 4.
• [35] AZGP1 inhibits soft tissue sarcoma cells invasion and migration.BMC Cancer. 2018 Jan 22;18(1):89. doi: 10.1186/s12885-017-3962-5.
• [36] Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer. 2007 Feb;43(3):601-6. doi: 10.1016/j.ejca.2006.09.024. Epub 2007 Jan 16.
• [37] Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas.Histopathology. 2018 Aug;73(2):299-305. doi: 10.1111/his.13525. Epub 2018 May 31.
• [38] c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.J Pathol. 2014 Oct;234(2):190-202. doi: 10.1002/path.4379. Epub 2014 Aug 1.
• [39] Design, Synthesis, and Characterization of Globular Orphan Nuclear Receptor Regulator with Biological Activity in Soft Tissue Sarcoma.J Med Chem. 2018 Dec 13;61(23):10739-10752. doi: 10.1021/acs.jmedchem.8b01387. Epub 2018 Nov 14.
• [40] PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.BMC Cancer. 2018 Jun 13;18(1):652. doi: 10.1186/s12885-018-4554-8.
• [41] New fusion sarcomas: histopathology and clinical significance of selected entities.Hum Pathol. 2019 Apr;86:57-65. doi: 10.1016/j.humpath.2018.12.006. Epub 2019 Jan 8.
• [42] Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.Sci Transl Med. 2014 May 21;6(237):237ra67. doi: 10.1126/scitranslmed.3007974.
• [43] NAC1, a BTB/POZ protein overexpressed in uterine sarcomas.Anticancer Res. 2012 Sep;32(9):3841-5.
• [44] The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements.Genes Chromosomes Cancer. 2019 Nov;58(11):739-746. doi: 10.1002/gcc.22767. Epub 2019 Jun 4.
• [45] Absence of mutation at the GAP-related domain of the neurofibromatosis type 1 gene in sporadic neurofibrosarcomas and other bone and soft tissue sarcomas.Cancer Genet Cytogenet. 1995 Jun;81(2):173-4. doi: 10.1016/0165-4608(94)00267-f.
• [46] Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.Mol Oncol. 2016 May;10(5):677-92. doi: 10.1016/j.molonc.2015.12.009. Epub 2015 Dec 20.
• [47] Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma.Mol Carcinog. 2007 Oct;46(10):865-71. doi: 10.1002/mc.20317.
• [48] Frequent absence of tumor suppressor FUS1 protein expression in human bone and soft tissue sarcomas.Anticancer Res. 2011 Jan;31(1):11-21.
• [49] High expression of the evolutionarily conserved alpha/beta hydrolase domain containing 6 (ABHD6) in Ewing tumors.Cancer Sci. 2009 Dec;100(12):2383-9. doi: 10.1111/j.1349-7006.2009.01347.x. Epub 2009 Sep 4.
• [50] Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.J Clin Invest. 2009 Jun;119(6):1727-40. doi: 10.1172/JCI37127. Epub 2009 May 18.
• [51] YAP1-Mediated Suppression of USP31 Enhances NFB Activity to Promote Sarcomagenesis.Cancer Res. 2018 May 15;78(10):2705-2720. doi: 10.1158/0008-5472.CAN-17-4052. Epub 2018 Feb 28.
• [52] Expression of dog1 in low-grade fibromyxoid sarcoma: A study of 19 cases and review of the literature.Ann Diagn Pathol. 2017 Oct;30:8-11. doi: 10.1016/j.anndiagpath.2017.05.002. Epub 2017 May 11.
• [53] Alterations of the p15, p16,and p18 genes in osteosarcoma.Cancer Genet Cytogenet. 1996 Feb;86(2):136-42. doi: 10.1016/0165-4608(95)00216-2.
• [54] Synthesis and Investigation of Photophysical and Biological Properties of Novel S-Containing Bacteriopurpurinimides.J Med Chem. 2017 Dec 28;60(24):10220-10230. doi: 10.1021/acs.jmedchem.7b00577. Epub 2017 Dec 18.
• [55] The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma.Br J Cancer. 2018 Mar 6;118(5):698-704. doi: 10.1038/bjc.2017.430. Epub 2017 Dec 12.
• [56] Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.Thorac Cancer. 2019 Dec;10(12):2312-2315. doi: 10.1111/1759-7714.13215. Epub 2019 Oct 16.
• [57] A systematic analysis of immune genes and overall survival in cancer patients.BMC Cancer. 2019 Dec 16;19(1):1225. doi: 10.1186/s12885-019-6414-6.
• [58] Cytogenetics and experimental models.Curr Opin Oncol. 1996 Jul;8(4):284-8. doi: 10.1097/00001622-199607000-00004.
• [59] Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.Lab Invest. 2019 Sep;99(9):1309-1320. doi: 10.1038/s41374-019-0263-4. Epub 2019 Jun 3.
• [60] Quantitative proteomic profiling of pleomorphic human sarcoma identifies CLIC1 as a dominant pro-oncogenic receptor expressed in diverse sarcoma types.J Proteome Res. 2014 May 2;13(5):2543-59. doi: 10.1021/pr4010713. Epub 2014 Apr 9.
• [61] Carboxypeptidase E: elevated expression correlated with tumor growth and metastasis in pheochromocytomas and other cancers.Cell Mol Neurobiol. 2010 Nov;30(8):1377-81. doi: 10.1007/s10571-010-9592-y.
• [62] Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent CRTC1-SS18 gene fusion.J Pathol. 2018 Jun;245(2):186-196. doi: 10.1002/path.5071. Epub 2018 Apr 16.
• [63] FMS Kinase Inhibitors: Current Status and Future Prospects.Med Res Rev. 2013 May;33(3):599-636. doi: 10.1002/med.21258. Epub 2012 Mar 20.
• [64] Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer. 2014 Aug 1;135(3):720-30.
• [65] Hepatitis B virus core protein promotes hepatocarcinogenesis by enhancing Src expression and activating the Src/PI3K/Akt pathway.FASEB J. 2018 Jun;32(6):3033-3046. doi: 10.1096/fj.201701144R. Epub 2018 Jan 17.
• [66] Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.J Biol Chem. 2018 Feb 16;293(7):2466-2475. doi: 10.1074/jbc.M117.805051. Epub 2017 Dec 1.
• [67] A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.Clin Cancer Res. 2019 Apr 1;25(7):2096-2108. doi: 10.1158/1078-0432.CCR-18-3496. Epub 2018 Dec 20.
• [68] Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index.Eur Radiol. 2020 Feb;30(2):914-924. doi: 10.1007/s00330-019-06445-9. Epub 2019 Oct 18.
• [69] Expression of embryonic lethal abnormal vision (ELAV)-like protein HuR and cyclooxygenase-2 (COX-2) in Ewing sarcoma.Tumori. 2008 May-Jun;94(3):347-50. doi: 10.1177/030089160809400310.
• [70] Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma.Orphanet J Rare Dis. 2017 May 23;12(1):97. doi: 10.1186/s13023-017-0647-8.
• [71] The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta-analysis.FEBS Open Bio. 2019 Oct;9(10):1744-1755. doi: 10.1002/2211-5463.12713. Epub 2019 Sep 3.
• [72] Solution structure of the Src homology 2 domain from the human feline sarcoma oncogene Fes.J Biomol NMR. 2005 Apr;31(4):357-61. doi: 10.1007/s10858-005-0946-6.
• [73] Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma.Mol Carcinog. 2012 Jul;51(7):515-21. doi: 10.1002/mc.20805. Epub 2011 Jun 7.
• [74] The mRNA expression of various angiogenesis-related genes in pediatric sarcomas and nonmalignant lesions of tissue.Pediatr Hematol Oncol. 2012 Feb;29(1):28-37. doi: 10.3109/08880018.2011.628366.
• [75] Expression profiles of signal transduction genes in ex vivo drug-resistant pediatric acute lymphoblastic leukemia.Anticancer Res. 2012 Feb;32(2):503-6.
• [76] Molecular analysis of a mutated FSH receptor detected in a patient with spontaneous ovarian hyperstimulation syndrome.PLoS One. 2013 Sep 13;8(9):e75478. doi: 10.1371/journal.pone.0075478. eCollection 2013.
• [77] YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1.J Cell Biol. 2015 Mar 30;208(7):913-29. doi: 10.1083/jcb.201411047. Epub 2015 Mar 23.
• [78] Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors.Pharmacogenet Genomics. 2017 Mar;27(3):112-119. doi: 10.1097/FPC.0000000000000264.
• [79] Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas.Int J Oncol. 2006 Aug;29(2):463-9.
• [80] Dasatinib Inhibits Procoagulant and Clot Retracting Activities of Human Platelets.Int J Mol Sci. 2019 Oct 31;20(21):5430. doi: 10.3390/ijms20215430.
• [81] Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2.Mol Cell Biol. 2016 Sep 12;36(19):2503-13. doi: 10.1128/MCB.00373-16. Print 2016 Oct 1.
• [82] Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients.Eur Radiol. 2019 Sep;29(9):4730-4741. doi: 10.1007/s00330-019-06017-x. Epub 2019 Feb 14.
• [83] Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors.BMC Cancer. 2009 Jan 14;9:17. doi: 10.1186/1471-2407-9-17.
• [84] PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.Endocr Pract. 2016 Sep;22(9):1081-7. doi: 10.4158/EP151057.OR. Epub 2016 May 23.
• [85] Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma.Oncogene. 2003 Jan 9;22(1):1-9. doi: 10.1038/sj.onc.1206055.
• [86] JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas.Cancer Cell. 2007 Apr;11(4):361-74. doi: 10.1016/j.ccr.2007.02.007.
• [87] Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes.Genes Chromosomes Cancer. 2012 May;51(5):510-20. doi: 10.1002/gcc.21939. Epub 2012 Feb 15.
• [88] Activation of transforming potential of the human insulin receptor gene.Proc Natl Acad Sci U S A. 1987 Aug;84(16):5725-9. doi: 10.1073/pnas.84.16.5725.
• [89] The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.Front Oncol. 2019 Jul 18;9:650. doi: 10.3389/fonc.2019.00650. eCollection 2019.
• [90] LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival.Cancer Biol Med. 2019 May;16(2):331-340. doi: 10.20892/j.issn.2095-3941.2018.0306.
• [91] LATS tumor suppressor: a new governor of cellular homeostasis.Cell Cycle. 2010 Oct 1;9(19):3892-903. doi: 10.4161/cc.9.19.13386. Epub 2010 Oct 20.
• [92] The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.Nat Med. 2000 Apr;6(4):429-34. doi: 10.1038/74689.
• [93] A novel triazolonaphthalimide induces apoptosis and inhibits tumor growth by targeting DNA and DNA-associated processes.Oncotarget. 2017 Jun 6;8(23):37394-37408. doi: 10.18632/oncotarget.16962.
• [94] Sarcoma of follicular dendritic cells with features of sinus lining cells--a new subtype of reticulum cell sarcoma?.Virchows Arch. 2008 May;452(5):565-70. doi: 10.1007/s00428-008-0603-z.
• [95] MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.Cancers (Basel). 2019 May 15;11(5):677. doi: 10.3390/cancers11050677.
• [96] Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IB.PLoS One. 2012;7(12):e52782. doi: 10.1371/journal.pone.0052782. Epub 2012 Dec 28.
• [97] Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4185-91. doi: 10.1158/1078-0432.CCR-03-0774.
• [98] The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.J Pathol. 2017 Mar;241(4):501-510. doi: 10.1002/path.4854. Epub 2017 Jan 6.
• [99] Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias.Genes Chromosomes Cancer. 2014 Jul;53(7):579-88. doi: 10.1002/gcc.22168. Epub 2014 Mar 24.
• [100] Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene.Cancer Genet Cytogenet. 2002 May;135(1):48-56. doi: 10.1016/s0165-4608(01)00641-0.
• [101] Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.PLoS Genet. 2015 Aug 21;11(8):e1005467. doi: 10.1371/journal.pgen.1005467. eCollection 2015 Aug.
• [102] Microsatellite instability and hMLH1 and hMSH2 expression analysis in soft tissue sarcomas.Oncol Rep. 2005 Feb;13(2):241-6.
• [103] Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma.Diagn Pathol. 2018 Oct 12;13(1):77. doi: 10.1186/s13000-018-0759-z.
• [104] The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-... Mol Cell Biol. 2009 Nov;29(21):5872-88.
• [105] Correlation of p16 and nm23-H1 expression levels with incidence and prognosis of soft tissue sarcoma.Oncol Lett. 2019 Jun;17(6):4865-4870. doi: 10.3892/ol.2019.10145. Epub 2019 Mar 13.
• [106] High expression of neuropeptide Y1 receptors in ewing sarcoma tumors.Clin Cancer Res. 2008 Aug 15;14(16):5043-9. doi: 10.1158/1078-0432.CCR-07-4551.
• [107] Emerging Targeted and Immune-Based Therapies in Sarcoma.J Clin Oncol. 2018 Jan 10;36(2):125-135. doi: 10.1200/JCO.2017.75.1610. Epub 2017 Dec 8.
• [108] Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms.Mod Pathol. 2019 Jul;32(7):1008-1022. doi: 10.1038/s41379-018-0184-6. Epub 2019 Mar 16.
• [109] Investigating a chimeric anti-mouse PDGFR antibody as a radiosensitizer in primary mouse sarcomas.EBioMedicine. 2019 Feb;40:224-230. doi: 10.1016/j.ebiom.2019.01.046. Epub 2019 Jan 31.
• [110] Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells.J Biol Chem. 2005 Jul 29;280(30):27544-51. doi: 10.1074/jbc.M411626200. Epub 2005 May 26.
• [111] The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005 Sep 23;122(6):835-47. doi: 10.1016/j.cell.2005.07.003.
• [112] p53 gene mutation and loss of heterozygosity of chromosome 11 in methylcholanthrene-induced mouse sarcomas.Jpn J Cancer Res. 1998 Mar;89(3):269-77. doi: 10.1111/j.1349-7006.1998.tb00558.x.
• [113] Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma.Mod Pathol. 2019 May;32(5):609-620. doi: 10.1038/s41379-018-0175-7. Epub 2018 Nov 21.
• [114] Genome-wide CRISPR Screen to Identify Genes that Suppress Transformation in the Presence of Endogenous Kras(G12D).Sci Rep. 2019 Nov 20;9(1):17220. doi: 10.1038/s41598-019-53572-w.
• [115] Uterine mesenchymal tumours: recent advances.Histopathology. 2020 Jan;76(1):64-75. doi: 10.1111/his.14008.
• [116] Increased Expression Of SOX2 Predicts A Poor Prognosis And Promotes Malignant Phenotypes In Upper Tract Urothelial Carcinoma.Cancer Manag Res. 2019 Oct 24;11:9095-9106. doi: 10.2147/CMAR.S219568. eCollection 2019.
• [117] Current knowledge of mechanisms of viral carcinogenesis.Crit Rev Toxicol. 1984;13(2):197-204. doi: 10.3109/10408448409034082.
• [118] In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors.Anticancer Res. 2003 May-Jun;23(3B):2465-71.
• [119] p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms.Oncotarget. 2016 Oct 4;7(40):64560-64574. doi: 10.18632/oncotarget.11656.
• [120] Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS.J Surg Oncol. 2019 Jun;119(7):824-835. doi: 10.1002/jso.25401. Epub 2019 Feb 8.
• [121] Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.Clin Orthop Relat Res. 2018 Sep;476(9):1848-1855. doi: 10.1097/CORR.0000000000000379.
• [122] Death Receptor 6 (DR6) Is Overexpressed in Astrocytomas.Anticancer Res. 2019 May;39(5):2299-2306. doi: 10.21873/anticanres.13346.
• [123] Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med. 2016 Apr 7;374(14):1391. doi: 10.1056/NEJMc1600338.
• [124] Rapamycin may inhibit murine S180 sarcoma growth by regulating the pathways associated with autophagy and cancer stem cells.J Cancer Res Ther. 2019;15(2):398-403. doi: 10.4103/jcrt.JCRT_639_18.
• [125] A novel POU homeodomain gene specifically expressed in cells of the developing mammalian nervous system.Nucleic Acids Res. 1992 Sep 25;20(18):4919-25. doi: 10.1093/nar/20.18.4919.
• [126] Association of a missense single nucleotide polymorphism, Cys1367Arg of the WRN gene, with the risk of bone and soft tissue sarcomas in Japan.Cancer Sci. 2008 Feb;99(2):333-9. doi: 10.1111/j.1349-7006.2007.00692.x.
• [127] Expression of CD56 and WT1 in ovarian stroma and ovarian stromal tumors.Am J Surg Pathol. 2008 Jun;32(6):884-90. doi: 10.1097/PAS.0b013e3181609d59.
• [128] Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma.JCI Insight. 2019 Jul 11;4(13):e128698. doi: 10.1172/jci.insight.128698.
• [129] MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1. World J Urol. 2018 Mar;36(3):357-365.
• [130] Next generation sequencing analysis of miRNAs: MiR-127-3p inhibits glioblastoma proliferation and activates TGF- signaling by targeting SKI.OMICS. 2014 Mar;18(3):196-206. doi: 10.1089/omi.2013.0122. Epub 2014 Feb 11.
• [131] [Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance].Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):445-8.
• [132] Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts.BMC Med Genet. 2019 May 3;20(1):69. doi: 10.1186/s12881-019-0808-9.
• [133] GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study.Ann Oncol. 2013 Nov;24(11):2922-6. doi: 10.1093/annonc/mdt391.
• [134] Definition of the human raf amino-terminal regulatory region by deletion mutagenesis.Mol Cell Biol. 1989 Feb;9(2):639-47. doi: 10.1128/mcb.9.2.639-647.1989.
• [135] The endogenous subcellular localisations of the long chain fatty acid-activating enzymes ACSL3 and ACSL4 in sarcoma and breast cancer cells.Mol Cell Biochem. 2018 Nov;448(1-2):275-286. doi: 10.1007/s11010-018-3332-x. Epub 2018 Feb 15.
• [136] Pol deficiency induces moderate shortening of P53(-/-) mouse lifespan and modifies tumor spectrum.DNA Repair (Amst). 2017 Jun;54:40-45. doi: 10.1016/j.dnarep.2017.04.001. Epub 2017 Apr 10.
• [137] Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities.J Pathol. 2018 Apr;244(5):638-649. doi: 10.1002/path.5042. Epub 2018 Mar 6.
• [138] Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.Lung Cancer. 2012 Jun;76(3):354-61. doi: 10.1016/j.lungcan.2011.12.002. Epub 2011 Dec 23.
• [139] Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.Cancer Res. 2014 Feb 1;74(3):921-31. doi: 10.1158/0008-5472.CAN-13-2424. Epub 2013 Dec 13.
• [140] Mutational analysis of high-grade spindle cell sarcoma of the femur in Mazabraud's syndrome.Skeletal Radiol. 2019 Jan;48(1):151-157. doi: 10.1007/s00256-018-2975-8. Epub 2018 May 27.
• [141] The Hippo signal transduction pathway in soft tissue sarcomas.Biochim Biophys Acta. 2015 Aug;1856(1):121-9. doi: 10.1016/j.bbcan.2015.05.006. Epub 2015 Jun 4.
• [142] Neoplastic Transformation of Human Mesenchymal Stromal Cells Mediated via LIN28B.Sci Rep. 2019 May 30;9(1):8101. doi: 10.1038/s41598-019-44536-1.
• [143] Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling.Mol Cancer Ther. 2020 Mar;19(3):742-754. doi: 10.1158/1535-7163.MCT-19-0358. Epub 2019 Dec 3.
• [144] Diagnostic utility of NCOA2 fluorescence in situ hybridization and Stat6 immunohistochemistry staining for soft tissue angiofibroma and morphologically similar fibrovascular tumors.Hum Pathol. 2014 Aug;45(8):1588-96. doi: 10.1016/j.humpath.2013.12.022. Epub 2014 Apr 18.
• [145] Elevated NDC80 expression is associated with poor prognosis in osteosarcoma patients.Eur Rev Med Pharmacol Sci. 2017 May;21(9):2045-2053.
• [146] Associations of clock genes polymorphisms with soft tissue sarcoma susceptibility and prognosis.J Transl Med. 2018 Dec 5;16(1):338. doi: 10.1186/s12967-018-1715-0.
• [147] NUTM2A-CIC fusion small round cell sarcoma: a genetically distinct variant of CIC-rearranged sarcoma.Hum Pathol. 2017 Jul;65:225-230. doi: 10.1016/j.humpath.2017.01.012. Epub 2017 Feb 8.
• [148] TGFBR3 and MGEA5 rearrangements are much more common in "hybrid" hemosiderotic fibrolipomatous tumor-myxoinflammatory fibroblastic sarcomas than in classical myxoinflammatory fibroblastic sarcomas: a morphological and fluorescence in situ hybridization study.Hum Pathol. 2016 Jul;53:14-24. doi: 10.1016/j.humpath.2016.02.005. Epub 2016 Mar 2.
• [149] Prognostic value of PLAGL1-specific CpG site methylation in soft-tissue sarcomas.PLoS One. 2013 Nov 15;8(11):e80741. doi: 10.1371/journal.pone.0080741. eCollection 2013.
• [150] Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity.Oncogene. 2001 Oct 18;20(47):6881-90. doi: 10.1038/sj.onc.1204874.
• [151] ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.J Pathol. 2017 Feb;241(3):316-323. doi: 10.1002/path.4836. Epub 2016 Dec 15.
• [152] Sequencing of DICER1 in sarcomas identifies biallelic somatic DICER1 mutations in an adult-onset embryonal rhabdomyosarcoma.Br J Cancer. 2017 Jun 6;116(12):1621-1626. doi: 10.1038/bjc.2017.147. Epub 2017 May 18.
• [153] Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.Cancer. 2010 Jun 15;116(12):2974-83. doi: 10.1002/cncr.25061.
• [154] Detection of SYT-SSX rearrangements in synovial sarcomas by real-time one-step RT-PCR.Pediatr Dev Pathol. 2005 Mar-Apr;8(2):162-7. doi: 10.1007/s10024-004-8097-4. Epub 2005 Mar 8.
• [155] TopBP1 promotes malignant progression and correlates with poor prognosis in osteosarcoma.Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4022-4031.
• [156] Genomic structure of SAS, a member of the transmembrane 4 superfamily amplified in human sarcomas.Genomics. 1995 Jan 20;25(2):501-6. doi: 10.1016/0888-7543(95)80051-m.
• [157] Inactivation of the tumor suppressor WTX in a subset of pediatric tumors.Genes Chromosomes Cancer. 2014 Jan;53(1):67-77. doi: 10.1002/gcc.22118. Epub 2013 Nov 5.
• [158] Aquaporin-1 and -5 are involved in the invasion and proliferation of soft tissue sarcomas.Pathol Res Pract. 2018 Jan;214(1):80-88. doi: 10.1016/j.prp.2017.11.006. Epub 2017 Nov 12.
• [159] High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma.PLoS One. 2013 Dec 20;8(12):e84187. doi: 10.1371/journal.pone.0084187. eCollection 2013.
• [160] Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology.Genes Chromosomes Cancer. 1998 May;22(1):16-25. doi: 10.1002/(sici)1098-2264(199805)22:1<16::aid-gcc3>3.0.co;2-a.
• [161] Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.Cancer Res. 1996 Mar 15;56(6):1219-21.
• [162] Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature.Front Oncol. 2018 Mar 1;8:45. doi: 10.3389/fonc.2018.00045. eCollection 2018.
• [163] Postoperative Day 1 Glucose May Be Associated With Wound Complications in Sarcomas Treated With Preoperative Radiation.Clin Orthop Relat Res. 2018 Mar;476(3):580-586. doi: 10.1007/s11999.0000000000000056.
• [164] ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma.Oncotarget. 2019 Jan 4;10(2):245-251. doi: 10.18632/oncotarget.26521. eCollection 2019 Jan 4.
• [165] Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas.PLoS One. 2010 Nov 19;5(11):e15541. doi: 10.1371/journal.pone.0015541.
• [166] Alveolar rhabdomyosarcoma in an adolescent male patient - case report and current perspectives.Rom J Morphol Embryol. 2018;59(4):1247-1252.
• [167] Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma.Cancer Manag Res. 2019 Sep 9;11:8209-8218. doi: 10.2147/CMAR.S218676. eCollection 2019.
• [168] Aberrant MAD2 expression in soft-tissue sarcoma.Pathol Int. 2008 Jun;58(6):329-33. doi: 10.1111/j.1440-1827.2008.02232.x.
• [169] Elevated frequency of a specific allele of the L-myc gene in male patients with bone and soft-tissue sarcomas.Int J Cancer. 1990 Jan 15;45(1):47-9. doi: 10.1002/ijc.2910450110.
• [170] Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.Acta Neuropathol. 2014 Apr;127(4):565-72. doi: 10.1007/s00401-014-1246-6. Epub 2014 Jan 25.
• [171] Expression of human Piwi-like genes is associated with prognosis for soft tissue sarcoma patients.BMC Cancer. 2012 Jun 29;12:272. doi: 10.1186/1471-2407-12-272.
• [172] The retinoblastoma family member pRb2/p130 is an independent predictor of survival in human soft tissue sarcomas.Clin Cancer Res. 2008 Aug 1;14(15):4775-9. doi: 10.1158/1078-0432.CCR-07-4055.
• [173] Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma.Clin Cancer Res. 2015 Feb 15;21(4):864-9. doi: 10.1158/1078-0432.CCR-14-2399. Epub 2014 Dec 16.
• [174] High Level of Perforin Expression Is Required for Effective Correction of Hemophagocytic Lymphohistiocytosis.Hum Gene Ther. 2016 Oct;27(10):847-859. doi: 10.1089/hum.2016.065. Epub 2016 Jul 29.
• [175] PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53.BMC Cancer. 2015 Oct 13;15:684. doi: 10.1186/s12885-015-1667-1.
• [176] Sarcoma in neurofibromatosis 2: case report and review of the literature.Fam Cancer. 2019 Jan;18(1):97-100. doi: 10.1007/s10689-018-0084-4.
• [177] Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma.J Hematol Oncol. 2014 Oct 10;7:76. doi: 10.1186/s13045-014-0076-2.
• [178] Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.Tumour Biol. 2014 Jun;35(6):5753-62. doi: 10.1007/s13277-014-1764-9. Epub 2014 Mar 2.
• [179] Kaposi Sarcoma in Association With an Extracavitary Primary Effusion Lymphoma Showing Unusual Intravascular Involvement: Report of a Case Harboring a FAM175A Germline Mutation.Am J Dermatopathol. 2020 Jan;42(1):55-60. doi: 10.1097/DAD.0000000000001491.
• [180] Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes.J Immunol. 1993 Dec 15;151(12):7161-71.
• [181] Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets.Mol Cancer Ther. 2009 Jan;8(1):249-60. doi: 10.1158/1535-7163.MCT-08-0636.
• [182] G-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1.J Pathol. 2013 May;230(1):70-81. doi: 10.1002/path.4170. Epub 2013 Mar 14.
• [183] Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas.Oncogene. 2011 Sep 22;30(38):4015-25. doi: 10.1038/onc.2011.108. Epub 2011 Apr 25.
• [184] The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation.Nat Med. 2007 Dec;13(12):1504-9. doi: 10.1038/nm1686. Epub 2007 Nov 25.
• [185] Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.Oncol Lett. 2019 Apr;17(4):3937-3943. doi: 10.3892/ol.2019.10044. Epub 2019 Feb 14.
• [186] The gene encoding the splicing factor SF2/ASF is a proto-oncogene.Nat Struct Mol Biol. 2007 Mar;14(3):185-93. doi: 10.1038/nsmb1209. Epub 2007 Feb 18.
• [187] Expression of MET in alveolar soft part sarcoma.Med Oncol. 2010 Jun;27(2):459-65. doi: 10.1007/s12032-009-9234-8. Epub 2009 May 27.
• [188] Cell-type dependent enhancer binding of the EWS/ATF1 fusion gene in clear cell sarcomas.Nat Commun. 2019 Sep 5;10(1):3999. doi: 10.1038/s41467-019-11745-1.
• [189] Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.PLoS Genet. 2019 Apr 10;15(4):e1008039. doi: 10.1371/journal.pgen.1008039. eCollection 2019 Apr.
• [190] Batf3-Dependent Genes Control Tumor Rejection Induced by Dendritic Cells Independently of Cross-Presentation.Cancer Immunol Res. 2019 Jan;7(1):29-39. doi: 10.1158/2326-6066.CIR-18-0138. Epub 2018 Nov 27.
• [191] Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas.PLoS One. 2013 Sep 3;8(9):e74738. doi: 10.1371/journal.pone.0074738. eCollection 2013.
• [192] Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.Oncotarget. 2017 Aug 24;8(44):77415-77423. doi: 10.18632/oncotarget.20492. eCollection 2017 Sep 29.
• [193] CIC-rearranged Sarcomas: A Study of 20 Cases and Comparisons With Ewing Sarcomas.Am J Surg Pathol. 2016 Mar;40(3):313-23. doi: 10.1097/PAS.0000000000000570.
• [194] Primary leiomyosarcoma of the spine: A case report and literature review.Medicine (Baltimore). 2017 Mar;96(9):e6227. doi: 10.1097/MD.0000000000006227.
• [195] Calpain-6 controls the fate of sarcoma stem cells by promoting autophagy and preventing senescence.JCI Insight. 2018 Sep 6;3(17):e121225. doi: 10.1172/jci.insight.121225. eCollection 2018 Sep 6.
• [196] A systematic analysis reveals gene expression alteration of serum deprivation response (SDPR) gene is significantly associated with the survival of patients with cancer.Oncol Rep. 2019 Sep;42(3):1161-1172. doi: 10.3892/or.2019.7212. Epub 2019 Jun 26.
• [197] CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma.Mol Med Rep. 2019 May;19(5):4205-4212. doi: 10.3892/mmr.2019.10104. Epub 2019 Mar 28.
• [198] In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type.Oncogene. 2005 Jun 23;24(27):4349-61. doi: 10.1038/sj.onc.1208620.
• [199] Clear cell sarcoma of the gastrointestinal tract and malignant gastrointestinal neuroectodermal tumour: distinct or related entities? A review.Pathology. 2018 Aug;50(5):490-498. doi: 10.1016/j.pathol.2018.05.001. Epub 2018 Jun 30.
• [200] Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas.Virchows Arch. 2008 Jul;453(1):89-96. doi: 10.1007/s00428-008-0608-7. Epub 2008 Apr 16.
• [201] Histological and immunohistochemical characteristics of undifferentiated small round cell sarcomas associated with CIC-DUX4 and BCOR-CCNB3 fusion genes.Virchows Arch. 2017 Apr;470(4):373-380. doi: 10.1007/s00428-017-2072-8. Epub 2017 Feb 14.
• [202] Chondroitin sulfate synthase 1 expression is associated with malignant potential of soft tissue sarcomas with myxoid substance.Hum Pathol. 2016 Apr;50:15-23. doi: 10.1016/j.humpath.2015.11.005. Epub 2015 Nov 22.
• [203] The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications.J Intern Med. 2009 Jul;266(1):43-52. doi: 10.1111/j.1365-2796.2009.02110.x.
• [204] Novel quinolone CHM-1 induces apoptosis and inhibits metastasis in a human osterogenic sarcoma cell line.J Orthop Res. 2009 Dec;27(12):1637-44. doi: 10.1002/jor.20937.
• [205] S-MED: sarcoma microRNA expression database.Lab Invest. 2010 May;90(5):753-61. doi: 10.1038/labinvest.2010.53. Epub 2010 Mar 8.
• [206] Engineering and characterization of a single-chain antibody fragment (scFV1924) against the human sarcoma-associated antigen p102.Anticancer Res. 2000 Jul-Aug;20(4):2753-60.
• [207] Low-grade fibromyxoid sarcoma with prominent giant rosettes and heterotopic ossification.Pathol Res Pract. 2012 Sep 15;208(9):557-60. doi: 10.1016/j.prp.2012.06.002. Epub 2012 Jul 20.
• [208] Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.Mol Cancer Ther. 2013 Apr;12(4):530-41. doi: 10.1158/1535-7163.MCT-12-0768. Epub 2013 Jan 30.
• [209] MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.J Pathol. 1996 Sep;180(1):58-64. doi: 10.1002/(SICI)1096-9896(199609)180:1<58::AID-PATH610>3.0.CO;2-W.
• [210] Alternative lengthening of telomeres does exist in various canine sarcomas.Mol Carcinog. 2017 Mar;56(3):923-935. doi: 10.1002/mc.22546. Epub 2016 Sep 22.
• [211] ARTEMIS stabilizes the genome and modulates proliferative responses in multipotent mesenchymal cells.BMC Biol. 2010 Oct 27;8:132. doi: 10.1186/1741-7007-8-132.
• [212] DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.BMC Cell Biol. 2009 Dec 17;10:89. doi: 10.1186/1471-2121-10-89.
• [213] Murine carcinoma expressing carcinoembryonic antigen-like protein is restricted by antibody against neem leaf glycoprotein.Immunol Lett. 2014 Nov;162(1 Pt A):132-9. doi: 10.1016/j.imlet.2014.08.004. Epub 2014 Aug 13.
• [214] CIC-DUX4 sarcoma diagnosed by fine-needle aspiration cytology: A case report.Diagn Cytopathol. 2018 Nov;46(11):958-963. doi: 10.1002/dc.24027. Epub 2018 Oct 24.
• [215] Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH.Mol Cancer. 2005 Nov 7;4:39. doi: 10.1186/1476-4598-4-39.
• [216] Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice.Neoplasia. 2010 Nov;12(11):915-27. doi: 10.1593/neo.10776.
• [217] Loss of TP53 in sarcomas with 17p12 to approximately p11 gain. A fine-resolution oligonucleotide array comparative genomic hybridization study.Cytogenet Genome Res. 2007;116(3):153-7. doi: 10.1159/000098180.
• [218] Chromosome 13 instability and esterase D expression in an osteosarcoma cell line.Cancer Genet Cytogenet. 1987 Feb;24(2):327-34. doi: 10.1016/0165-4608(87)90115-4.
• [219] Separase loss of function cooperates with the loss of p53 in the initiation and progression of T- and B-cell lymphoma, leukemia and aneuploidy in mice.PLoS One. 2011;6(7):e22167. doi: 10.1371/journal.pone.0022167. Epub 2011 Jul 25.
• [220] The utility of ETV1, ETV4 and ETV5 RNA in-situ hybridization in the diagnosis of CIC-DUX sarcomas.Histopathology. 2017 Mar;70(4):657-663. doi: 10.1111/his.13112. Epub 2016 Dec 16.
• [221] fau cDNA encodes a ubiquitin-like-S30 fusion protein and is expressed as an antisense sequence in the Finkel-Biskis-Reilly murine sarcoma virus.Oncogene. 1993 Sep;8(9):2537-46.
• [222] Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis.Cell Metab. 2020 Jan 7;31(1):174-188.e7. doi: 10.1016/j.cmet.2019.10.012. Epub 2019 Nov 21.
• [223] Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV.J Mol Diagn. 2007 Sep;9(4):459-63. doi: 10.2353/jmoldx.2007.070009. Epub 2007 Jul 9.
• [224] Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling.Mol Carcinog. 2015 Sep;54(9):841-52. doi: 10.1002/mc.22155. Epub 2014 Apr 9.
• [225] FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma.Appl Immunohistochem Mol Morphol. 2011 May;19(3):233-8. doi: 10.1097/PAI.0b013e3181fd6697.
• [226] Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.APMIS. 2012 Aug;120(8):635-9. doi: 10.1111/j.1600-0463.2012.02878.x. Epub 2012 Mar 24.
• [227] A novel CIC-FOXO4 gene fusion in undifferentiated small round cell sarcoma: a genetically distinct variant of Ewing-like sarcoma.Am J Surg Pathol. 2014 Nov;38(11):1571-6. doi: 10.1097/PAS.0000000000000286.
• [228] Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling.Cancer Res. 2008 May 1;68(9):3350-60. doi: 10.1158/0008-5472.CAN-07-3220.
• [229] Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism.Mol Cell Biol. 2008 Apr;28(7):2368-79. doi: 10.1128/MCB.01780-07. Epub 2008 Jan 22.
• [230] Grb2-associated binding protein-1 as a biomarker in bone and soft tissue sarcomas.Pathology. 2019 Oct;51(6):610-614. doi: 10.1016/j.pathol.2019.05.003. Epub 2019 Aug 20.
• [231] Transcriptional Dynamics of Immortalized Human Mesenchymal Stem Cells during Transformation.PLoS One. 2015 May 15;10(5):e0126562. doi: 10.1371/journal.pone.0126562. eCollection 2015.
• [232] Orphan G protein-coupled receptor GPRC5A modulates integrin 1-mediated epithelial cell adhesion.Cell Adh Migr. 2017 Sep 3;11(5-6):434-446. doi: 10.1080/19336918.2016.1245264. Epub 2017 Feb 6.
• [233] Hice1, a novel microtubule-associated protein required for maintenance of spindle integrity and chromosomal stability in human cells.Mol Cell Biol. 2008 Jun;28(11):3652-62. doi: 10.1128/MCB.01923-07. Epub 2008 Mar 24.
• [234] hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells.Nucleic Acids Res. 2017 Dec 1;45(21):12270-12284. doi: 10.1093/nar/gkx831.
• [235] Autophagy regulates amyotrophic lateral sclerosis-linked fused in sarcoma-positive stress granules in neurons.Neurobiol Aging. 2014 Dec;35(12):2822-2831. doi: 10.1016/j.neurobiolaging.2014.07.026. Epub 2014 Jul 27.
• [236] Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas.Genes Chromosomes Cancer. 2006 Sep;45(9):829-38. doi: 10.1002/gcc.20343.
• [237] YWHAE Rearrangement in a Purely Conventional Low-grade Endometrial Stromal Sarcoma that Transformed Over Time to High-grade Sarcoma: Importance of Molecular Testing.Int J Gynecol Pathol. 2018 Sep;37(5):441-447. doi: 10.1097/PGP.0000000000000451.
• [238] Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells.Oncogene. 2006 May 4;25(19):2795-800. doi: 10.1038/sj.onc.1209300.
• [239] Does a less intensive surveillance protocol affect the survival of patients after treatment of a sarcoma of the limb? updated results of the randomized TOSS study.Bone Joint J. 2018 Feb;100-B(2):262-268. doi: 10.1302/0301-620X.100B2.BJJ-2017-0789.R1.
• [240] Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas.Clin Cancer Res. 2011 Apr 1;17(7):1828-38. doi: 10.1158/1078-0432.CCR-10-2066. Epub 2011 Feb 16.
• [241] Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182.Cancer Lett. 2015 Dec 1;369(1):202-11. doi: 10.1016/j.canlet.2015.08.016. Epub 2015 Aug 24.
• [242] Retinoic acid receptor and retinoid X receptor expression in retinoic acid-resistant human tumor cell lines.Mol Carcinog. 1993;8(2):112-22. doi: 10.1002/mc.2940080208.
• [243] Discovery and characterization of two novel human cancer-related proteins using two-dimensional gel electrophoresis.Electrophoresis. 1994 Mar-Apr;15(3-4):345-57. doi: 10.1002/elps.1150150154.
• [244] LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.Cancer Res. 2018 Jul 15;78(14):4059-4072. doi: 10.1158/0008-5472.CAN-18-0327. Epub 2018 May 15.
• [245] Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma.Nat Genet. 2014 Jul;46(7):666-8. doi: 10.1038/ng.2989. Epub 2014 May 25.
• [246] Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: Correlations with Ki-67 and P53 expression, and apoptosis.Int J Mol Med. 2002 Aug;10(2):161-8.
• [247] MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol 3-kinase/Akt-induced transformation.Mol Cell Biol. 2013 Nov;33(22):4473-91. doi: 10.1128/MCB.01050-13. Epub 2013 Sep 16.
• [248] Sarcoma with MGA-NUTM1 fusion in the lung: an emerging entity.Virchows Arch. 2020 Feb;476(2):317-322. doi: 10.1007/s00428-019-02623-8. Epub 2019 Aug 5.
• [249] High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic/dendritic cell sarcomas.Am J Surg Pathol. 2009 Jun;33(6):863-73. doi: 10.1097/PAS.0b013e31819287b8.
• [250] RREB1-MKL2 fusion in biphenotypic "oropharyngeal" sarcoma: New entity or part of the spectrum of biphenotypic sinonasal sarcomas?.Genes Chromosomes Cancer. 2018 Apr;57(4):203-210. doi: 10.1002/gcc.22521. Epub 2018 Jan 25.
• [251] MUC5AC/-catenin expression and KRAS gene alteration in laterally spreading colorectal tumors.World J Gastroenterol. 2012 Oct 21;18(39):5551-9. doi: 10.3748/wjg.v18.i39.5551.
• [252] Human smooth muscle myosin light chain-2 gene expression is repressed in ras transformed fibroblast cells.Cell Growth Differ. 1992 Jan;3(1):1-10.
• [253] Beyond "Triton": Malignant Peripheral Nerve Sheath Tumors With Complete Heterologous Rhabdomyoblastic Differentiation Mimicking Spindle Cell Rhabdomyosarcoma.Am J Surg Pathol. 2019 Oct;43(10):1323-1330. doi: 10.1097/PAS.0000000000001290.
• [254] Amplification and protein expression of chromosome 12q13-15 genes in osteosarcomas of the jaws.Oral Oncol. 2001 Oct;37(7):566-71. doi: 10.1016/s1368-8375(00)00130-5.
• [255] EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.Eur Respir J. 2014 Mar;43(3):872-83. doi: 10.1183/09031936.00018013. Epub 2013 Aug 29.
• [256] EWSR1-NFATC2 Translocation-associated Sarcoma Clinicopathologic Findings in a Rare Aggressive Primary Bone or Soft Tissue Tumor.Am J Surg Pathol. 2019 Aug;43(8):1112-1122. doi: 10.1097/PAS.0000000000001260.
• [257] PAX7 immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours.Histopathology. 2018 Oct;73(4):645-652. doi: 10.1111/his.13689. Epub 2018 Aug 2.
• [258] The gene expression profile of extraskeletal myxoid chondrosarcoma.J Pathol. 2005 Aug;206(4):433-44. doi: 10.1002/path.1792.
• [259] Anti-tumor and immunomodulatory activities induced by an alkali-extracted polysaccharide BCAP-1 from Bupleurum chinense via NF-B signaling pathway.Int J Biol Macromol. 2017 Feb;95:357-362. doi: 10.1016/j.ijbiomac.2016.10.112. Epub 2016 Nov 22.
• [260] Genomic organization of the OS-9 gene amplified in human sarcomas.J Biochem. 1997 Dec;122(6):1190-5. doi: 10.1093/oxfordjournals.jbchem.a021880.
• [261] Cloning of P2XM, a novel human P2X receptor gene regulated by p53.Cancer Res. 1997 Aug 1;57(15):3281-7.
• [262] Ewing sarcoma and Ewing-like tumors.Virchows Arch. 2020 Jan;476(1):109-119. doi: 10.1007/s00428-019-02720-8. Epub 2019 Dec 4.
• [263] The expression and function of PAX3 in development and disease.Gene. 2018 Aug 5;666:145-157. doi: 10.1016/j.gene.2018.04.087. Epub 2018 May 4.
• [264] Inflammatory leiomyosarcoma is a distinct tumor characterized by near-haploidization, few somatic mutations, and a primitive myogenic gene expression signature.Mod Pathol. 2018 Jan;31(1):93-100. doi: 10.1038/modpathol.2017.113. Epub 2017 Sep 8.
• [265] Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft-tissue sarcoma.Oncogene. 2007 Feb 15;26(7):1098-100. doi: 10.1038/sj.onc.1209880. Epub 2006 Sep 4.
• [266] Perilipin 1 is a highly specific marker for adipocytic differentiation in sarcomas with intermediate sensitivity.J Cancer Res Clin Oncol. 2017 Feb;143(2):225-232. doi: 10.1007/s00432-016-2263-8. Epub 2016 Sep 19.
• [267] Soft tissue sarcoma and the hereditary non-polyposis colorectal cancer (HNPCC) syndrome: formulation of an hypothesis.Mol Biol Rep. 2012 Oct;39(10):9307-10. doi: 10.1007/s11033-012-1729-2. Epub 2012 Jul 11.
• [268] The wide spectrum of POT1 gene variants correlates with multiple cancer types.Eur J Hum Genet. 2017 Nov;25(11):1278-1281. doi: 10.1038/ejhg.2017.134. Epub 2017 Aug 30.
• [269] Sarcoma family kinase activity is required for cortical spreading depression.Cephalalgia. 2018 Oct;38(11):1748-1758. doi: 10.1177/0333102417748572. Epub 2017 Dec 14.
• [270] Arginine methyltransferase inhibitor-1 inhibits sarcoma viability in vitro and in vivo.Oncol Lett. 2018 Aug;16(2):2161-2166. doi: 10.3892/ol.2018.8929. Epub 2018 Jun 8.
• [271] PP2A:B56{epsilon}, a substrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development.J Biol Chem. 2010 Nov 5;285(45):34493-502. doi: 10.1074/jbc.M110.169581. Epub 2010 Aug 31.
• [272] Impact of expression of the uPA system in sarcomas.Biomark Med. 2013 Jun;7(3):473-80. doi: 10.2217/bmm.12.105.
• [273] A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells.Cancer Res. 1993 Apr 1;53(7):1498-502.
• [274] Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.J Biol Chem. 2014 Aug 8;289(32):22035-47. doi: 10.1074/jbc.M114.568725. Epub 2014 Jun 24.
• [275] Cellular retinol-binding protein I, a regulator of breast epithelial retinoic acid receptor activity, cell differentiation, and tumorigenicity.J Natl Cancer Inst. 2005 Jan 5;97(1):21-9. doi: 10.1093/jnci/dji004.
• [276] Neuron-restrictive silencer factor-mediated downregulation of -opioid receptor contributes to the reduced morphine analgesia in bone cancer pain.Pain. 2017 May;158(5):879-890. doi: 10.1097/j.pain.0000000000000848.
• [277] IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.Mol Cancer Ther. 2012 Jun;11(6):1247-56. doi: 10.1158/1535-7163.MCT-11-0913. Epub 2012 Mar 28.
• [278] Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells.PLoS One. 2010 Nov 30;5(11):e14154. doi: 10.1371/journal.pone.0014154.
• [279] Does Patellar Tendon Repair With Gastrocnemius Flap Augmentation Effectively Restore Active Extension After Proximal Tibial Sarcoma Resection?.Clin Orthop Relat Res. 2019 Mar;477(3):584-593. doi: 10.1097/CORR.0000000000000564.
• [280] Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.Cancer Res. 2010 Nov 1;70(21):8770-81. doi: 10.1158/0008-5472.CAN-10-1093. Epub 2010 Oct 19.
• [281] Primary mediastinal synovial sarcoma with subsequent development of primary adenoid cystic carcinoma of lung presenting as superior vena cava syndrome.Clin Respir J. 2018 Jan;12(1):306-311. doi: 10.1111/crj.12476. Epub 2016 Oct 18.
• [282] Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology.Am J Pathol. 2003 Oct;163(4):1449-56. doi: 10.1016/S0002-9440(10)63502-X.
• [283] Secretogranin II expression in Ewing's sarcomas and primitive neuroectodermal tumors.Diagn Mol Pathol. 1992 Sep;1(3):165-72.
• [284] Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI).Int J Hyperthermia. 2017 Aug;33(5):520-527. doi: 10.1080/02656736.2017.1301576.
• [285] Functional characterization of obesity-associated variants involving the and isoforms of human SH2B1.Endocrinology. 2014 Sep;155(9):3219-26. doi: 10.1210/en.2014-1264. Epub 2014 Jun 27.
• [286] A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.PLoS One. 2011;6(12):e28277. doi: 10.1371/journal.pone.0028277. Epub 2011 Dec 14.
• [287] When the guardian sleeps: Reactivation of the p53 pathway in cancer.Mutat Res Rev Mutat Res. 2017 Jul;773:1-13. doi: 10.1016/j.mrrev.2017.02.003. Epub 2017 Feb 17.
• [288] The transcription factor Sp3 regulates the expression of a metastasis-related marker of sarcoma, actin filament-associated protein 1-like 1 (AFAP1L1).PLoS One. 2013;8(1):e49709. doi: 10.1371/journal.pone.0049709. Epub 2013 Jan 9.
• [289] Evaluation of expression of cancer stem cell markers and fusion gene in synovial sarcoma: Insights into histogenesis and pathogenesis.Oncol Rep. 2017 Jun;37(6):3351-3360. doi: 10.3892/or.2017.5617. Epub 2017 May 2.
• [290] Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas.BMC Cancer. 2014 Feb 17;14:100. doi: 10.1186/1471-2407-14-100.
• [291] Purification and characterization of human lung fibroblast motility-stimulating factor for human soft tissue sarcoma cells: identification as an NH2-terminal fragment of human fibronectin.Cancer Res. 1997 Aug 15;57(16):3577-84.
• [292] mRNA and protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma.Genes Chromosomes Cancer. 2011 May;50(5):338-47. doi: 10.1002/gcc.20858. Epub 2011 Feb 22.
• [293] Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma.Int J Cancer. 2003 Nov 1;107(2):317-22. doi: 10.1002/ijc.11369.
• [294] SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.Mod Pathol. 2017 Oct;30(10):1422-1432. doi: 10.1038/modpathol.2017.61. Epub 2017 Jun 23.
• [295] Suppression of tubulin tyrosine ligase during tumor growth.J Cell Sci. 1998 Jan;111 ( Pt 2):171-81. doi: 10.1242/jcs.111.2.171.
• [296] First case of B ALL with KMT2A-MAML2 rearrangement: a case report.BMC Cancer. 2017 May 23;17(1):363. doi: 10.1186/s12885-017-3368-4.
• [297] Detection of LOH of the RB1 gene in bladder cancers by PCR-RFLP.Urol Int. 2002;68(3):189-92. doi: 10.1159/000048448.
• [298] Immunohistochemical correlates of recurrent genetic alterations in sarcomas.Genes Chromosomes Cancer. 2019 Feb;58(2):111-123. doi: 10.1002/gcc.22700. Epub 2018 Dec 19.